EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial

Paula de Melo Campos iD, Kátia Borgia Barbosa Pagnano, Fernanda Soares Niemann, Rubia Isler Mancuso, Fernanda Isabel Della Via, Ada Congrains iD, Juan Luiz Coelho-Silva, Ângela Condotta Tinoco, Guilherme Rossi Assis-Mendonça, Leandro Luiz Lopes de Freitas, Fabiola Traina, Sara T Olalla Saad iD

Hematological Oncology · 2026

DOI: 10.1002/hon.70163 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Hematological Oncology, 2026. Verfasst von Paula de Melo Campos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Transfusion Medicine Center, Universidade Estadual de Campinas (Unicamp), Sao Paulo, Brazil. Hauptthemen laut MEDLINE: Metformin, Primary Myelofibrosis, Signal Transduction, STAT Transcription Factors. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasil, São Paulo Research Foundation (FAPESP), Brasil, Instituto Nacional de Ciência e Tecnologia do Sangue (INCTS), Brasil.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by the activation of the JAK‐STAT pathway. Previous evidence showed that metformin might be a possible therapeutic option for treating JAK2‐mediated myeloproliferative neoplasms. In vitro and in vivo studies demonstrated that metformin inhibits the JAK‐STAT pathway, induces apoptosis in JAK2 V617F ‐positive cell lines and reduces tumor burden and splenomegaly in Jak2 V617F knock‐in‐induced mice. The FIBROMET trial, an open label phase II study, evaluated metformin effects on 10 primary myelofibrosis patients over 2 years of treatment. Primary endpoint was bone marrow fibrosis reduction. Secondary endpoints were constitutional symptoms, blood counts, spleen size modulation and exploratory evaluation of protein and gene expression. Metformin treatment reduced bone marrow collagen deposits, downregulated the STAT pathway and reduced the p85 subunit of PI3K enzymatic complex, together with endothelial maintenance genes, in PMF patients. These results raise new evidence regarding metformin, a cheap and widely available drug, as a possible adjuvant for the treatment of PMF patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminPrimary MyelofibrosisSignal TransductionSTAT Transcription FactorsBone MarrowHumansMaleFemaleMiddle AgedAgedAnimalsMiceAdultDown-RegulationFibrosis

Stichwörter der Autor:innen

FIBROMETJAK‐STATfibrosismetforminmyelofibrosis

Substanzen

MetforminSTAT Transcription Factors

Autor:innen und Institutionen

  • Hematology and Transfusion Medicine Center, Universidade Estadual de Campinas (Unicamp), Sao Paulo, Brazil.
  • Department of Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Department of Pathology, Universidade Estadual de Campinas (Unicamp), Sao Paulo, Brazil.

ORCID-Profile: Paula de Melo Campos, Ada Congrains, Sara T Olalla Saad

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasil
  • São Paulo Research Foundation (FAPESP), Brasil
  • Instituto Nacional de Ciência e Tecnologia do Sangue (INCTS), Brasil

Zitieren

APA

Melo Campos, P., Pagnano, K. B. B., Niemann, F. S., Mancuso, R. I., Della Via, F. I., Congrains, A., Coelho-Silva, J. L., Tinoco, Â. C., Assis-Mendonça, G. R., Freitas, L. L. L., Traina, F., & Saad, S. T. O. (2026). Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial. Hematological Oncology. https://doi.org/10.1002/hon.70163

Vancouver

Melo Campos P, Pagnano KBB, Niemann FS, Mancuso RI, Della Via FI, Congrains A, et al. Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial. Hematological Oncology. 2026. doi:10.1002/hon.70163

BibTeX
@article{MeloCampos2026,
  author = {Melo Campos, Paula de and Pagnano, Kátia Borgia Barbosa and Niemann, Fernanda Soares and Mancuso, Rubia Isler and Della Via, Fernanda Isabel and Congrains, Ada and Coelho-Silva, Juan Luiz and Tinoco, Ângela Condotta and Assis-Mendonça, Guilherme Rossi and Freitas, Leandro Luiz Lopes de and Traina, Fabiola and Saad, Sara T Olalla},
  title = {Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70163}
}
Kostenlos starten →